Jin Medical International Approves Share Combination Plan
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 23 hours ago
0mins
Should l Buy ZJYL?
Source: Newsfilter
- Share Combination Plan: Jin Medical International's Board of Directors has approved a 1-for-20 share combination aimed at enhancing the company's capital structure by reducing the number of outstanding shares, thereby improving compliance with Nasdaq listing requirements and market performance.
- Authorized Capital Reclassification: The reclassification divides the company's authorized capital into 45 million Class A ordinary shares and 5 million Class B ordinary shares, reflecting a strategic adjustment in capital structure that is expected to attract more investor interest.
- Market Trading Arrangement: The stock combination will take effect on March 16, 2026, with Class A ordinary shares continuing to trade on Nasdaq under a consolidation-adjusted basis, and the new CUSIP number will be G5140V120, ensuring a smooth transition for investors.
- Production Facility Expansion: Jin Medical's manufacturing facilities in Jiangsu and Anhui provinces will total 660,000 square feet, indicating the company's ongoing efforts to expand production capacity and market share to meet the growing demand from the disabled and elderly markets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZJYL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZJYL
About ZJYL
Jin Medical International Ltd is a holding company mainly engaged in the design and manufacturing of wheelchairs. The Company, through its wholly owned subsidiaries, is primarily engaged in the design, development, manufacturing and sales of wheelchair and other living aids products to be used by people with disabilities or impaired mobility. The Company's wheelchair product category includes mid, high and low-end wheelchairs. The wheelchair components include wheels and brakes, which are sold to customers for after-sales service. The living aids product category consists of oxygen concentrators, bath aids and rehabilitative devices. The Company mainly distributes its products in domestic and overseas markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Jin Medical International Approves Share Combination Plan
- Share Combination Plan: Jin Medical International's Board of Directors has approved a 1-for-20 share combination aimed at enhancing the company's capital structure by reducing the number of outstanding shares, thereby improving compliance with Nasdaq listing requirements and market performance.
- Authorized Capital Reclassification: The reclassification divides the company's authorized capital into 45 million Class A ordinary shares and 5 million Class B ordinary shares, reflecting a strategic adjustment in capital structure that is expected to attract more investor interest.
- Market Trading Arrangement: The stock combination will take effect on March 16, 2026, with Class A ordinary shares continuing to trade on Nasdaq under a consolidation-adjusted basis, and the new CUSIP number will be G5140V120, ensuring a smooth transition for investors.
- Production Facility Expansion: Jin Medical's manufacturing facilities in Jiangsu and Anhui provinces will total 660,000 square feet, indicating the company's ongoing efforts to expand production capacity and market share to meet the growing demand from the disabled and elderly markets.
See More
Jin Medical International Approves 1-for-20 Reverse Stock Split
- Reverse Stock Split Plan: Jin Medical International Ltd. has approved a 1-for-20 reverse stock split, set to take effect on March 16, 2026, which will significantly reduce the number of outstanding shares as part of its effort to regain compliance with Nasdaq listing requirements.
- Share Count Reduction: Following the split, the number of issued Class A shares will decrease from approximately 136.5 million to about 6.8 million, while Class B shares will shrink from 20 million to 1 million, thereby optimizing the company's capital structure.
- Capital Structure Reclassification: The company has completed the reclassification of its authorized capital into dual-class shares and filed updated corporate documents with regulators in the Cayman Islands to reflect these changes, indicating a focus on strengthening its long-term capital framework.
- Stock Price Fluctuation: ZJYL shares have traded between $0.11 and $1.02 over the past year, currently priced at $0.11, down 18.90%, reflecting market caution regarding the company's future prospects.
See More
Jin Medical International Approves 1-for-20 Reverse Stock Split
- Reverse Stock Split Decision: Jin Medical International (ZJYL) has approved a 1-for-20 reverse stock split, set to take effect on March 16, 2026, which is expected to significantly reduce the total number of authorized and issued shares, potentially impacting shareholder structure profoundly.
- Share Count Changes: Following the reverse split, Class A shares will decrease from 136.55 million to 6.83 million, while Class B shares will drop from 20 million to 1 million, a change that will notably increase the market value per share and may influence investor holding decisions.
- Equity Structure Reclassification: The company has reclassified its share structure into dual classes, establishing 45 million Class A shares and 5 million Class B shares, aiming to enhance governance and operational flexibility, thereby increasing market appeal.
- Market Reaction: Following the announcement of the reverse split, ZJYL's shares fell 16% in premarket trading, reflecting a cautious market sentiment regarding this decision, which could affect investor confidence and future financing capabilities.
See More
Jin Medical International Announces Share Combination Plan
- Share Combination Plan: Jin Medical International's Board of Directors has approved a 1-for-20 share combination aimed at enhancing the company's capital structure by reducing the number of outstanding shares, thereby improving compliance with Nasdaq listing requirements and market performance.
- Authorized Capital Reclassification: Following the authorization from the extraordinary general meeting on January 30, 2026, the company will reclassify its authorized capital into Class A and Class B ordinary shares, totaling $50,000, reflecting strategic planning for future growth.
- Shareholder Structure Change: Post-combination, the number of outstanding Class A ordinary shares will decrease from 136,547,100 to 6,827,355, while Class B ordinary shares will drop from 20,000,000 to 1,000,000, significantly increasing per-share value and boosting investor confidence.
- New Trading Code Effective: The share combination will take effect on March 16, 2026, with Class A ordinary shares continuing to trade on Nasdaq under the existing symbol
See More
Healthcare Stocks Surge in After-Hours Trading
- Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
- Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
- Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
- Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
See More
Jin Medical International to Host Strategic Discussion
- Executive Strategic Discussion: Jin Medical's CEO and management team will host a strategic discussion on February 1, 2026, at 8 PM EST, aimed at sharing recent strategic priorities and long-term growth considerations, which is expected to enhance investor confidence.
- Website Update Launch: The company has launched its updated corporate website, providing a webcast of the strategic discussion, thereby increasing information transparency and offering investors a more convenient channel to access company updates.
- Manufacturing Capacity Expansion: Jin Medical operates two manufacturing plants in Jiangsu Province totaling approximately 230,000 square feet and is establishing a new facility of 430,000 square feet in Chuzhou, Anhui Province, demonstrating the company's proactive response to future market demand.
- International Distribution Network: Jin Medical collaborates with over 40 domestic distributors and more than 20 international distributors, primarily selling over 30 lightweight and ergonomic wheelchair models to Japan and China, further solidifying its leadership position in the rehabilitation medical equipment market.
See More
Jin Medical International Approves Share Combination Plan
- Share Combination Plan: Jin Medical International's Board of Directors has approved a 1-for-20 share combination aimed at enhancing the company's capital structure by reducing the number of outstanding shares, thereby improving compliance with Nasdaq listing requirements and market performance.
- Authorized Capital Reclassification: The reclassification divides the company's authorized capital into 45 million Class A ordinary shares and 5 million Class B ordinary shares, reflecting a strategic adjustment in capital structure that is expected to attract more investor interest.
- Market Trading Arrangement: The stock combination will take effect on March 16, 2026, with Class A ordinary shares continuing to trade on Nasdaq under a consolidation-adjusted basis, and the new CUSIP number will be G5140V120, ensuring a smooth transition for investors.
- Production Facility Expansion: Jin Medical's manufacturing facilities in Jiangsu and Anhui provinces will total 660,000 square feet, indicating the company's ongoing efforts to expand production capacity and market share to meet the growing demand from the disabled and elderly markets.
See More
Jin Medical International Approves 1-for-20 Reverse Stock Split
- Reverse Stock Split Plan: Jin Medical International Ltd. has approved a 1-for-20 reverse stock split, set to take effect on March 16, 2026, which will significantly reduce the number of outstanding shares as part of its effort to regain compliance with Nasdaq listing requirements.
- Share Count Reduction: Following the split, the number of issued Class A shares will decrease from approximately 136.5 million to about 6.8 million, while Class B shares will shrink from 20 million to 1 million, thereby optimizing the company's capital structure.
- Capital Structure Reclassification: The company has completed the reclassification of its authorized capital into dual-class shares and filed updated corporate documents with regulators in the Cayman Islands to reflect these changes, indicating a focus on strengthening its long-term capital framework.
- Stock Price Fluctuation: ZJYL shares have traded between $0.11 and $1.02 over the past year, currently priced at $0.11, down 18.90%, reflecting market caution regarding the company's future prospects.
See More
Jin Medical International Approves 1-for-20 Reverse Stock Split
- Reverse Stock Split Decision: Jin Medical International (ZJYL) has approved a 1-for-20 reverse stock split, set to take effect on March 16, 2026, which is expected to significantly reduce the total number of authorized and issued shares, potentially impacting shareholder structure profoundly.
- Share Count Changes: Following the reverse split, Class A shares will decrease from 136.55 million to 6.83 million, while Class B shares will drop from 20 million to 1 million, a change that will notably increase the market value per share and may influence investor holding decisions.
- Equity Structure Reclassification: The company has reclassified its share structure into dual classes, establishing 45 million Class A shares and 5 million Class B shares, aiming to enhance governance and operational flexibility, thereby increasing market appeal.
- Market Reaction: Following the announcement of the reverse split, ZJYL's shares fell 16% in premarket trading, reflecting a cautious market sentiment regarding this decision, which could affect investor confidence and future financing capabilities.
See More
Jin Medical International Announces Share Combination Plan
- Share Combination Plan: Jin Medical International's Board of Directors has approved a 1-for-20 share combination aimed at enhancing the company's capital structure by reducing the number of outstanding shares, thereby improving compliance with Nasdaq listing requirements and market performance.
- Authorized Capital Reclassification: Following the authorization from the extraordinary general meeting on January 30, 2026, the company will reclassify its authorized capital into Class A and Class B ordinary shares, totaling $50,000, reflecting strategic planning for future growth.
- Shareholder Structure Change: Post-combination, the number of outstanding Class A ordinary shares will decrease from 136,547,100 to 6,827,355, while Class B ordinary shares will drop from 20,000,000 to 1,000,000, significantly increasing per-share value and boosting investor confidence.
- New Trading Code Effective: The share combination will take effect on March 16, 2026, with Class A ordinary shares continuing to trade on Nasdaq under the existing symbol
See More
Healthcare Stocks Surge in After-Hours Trading
- Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
- Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
- Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
- Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
See More
Jin Medical International to Host Strategic Discussion
- Executive Strategic Discussion: Jin Medical's CEO and management team will host a strategic discussion on February 1, 2026, at 8 PM EST, aimed at sharing recent strategic priorities and long-term growth considerations, which is expected to enhance investor confidence.
- Website Update Launch: The company has launched its updated corporate website, providing a webcast of the strategic discussion, thereby increasing information transparency and offering investors a more convenient channel to access company updates.
- Manufacturing Capacity Expansion: Jin Medical operates two manufacturing plants in Jiangsu Province totaling approximately 230,000 square feet and is establishing a new facility of 430,000 square feet in Chuzhou, Anhui Province, demonstrating the company's proactive response to future market demand.
- International Distribution Network: Jin Medical collaborates with over 40 domestic distributors and more than 20 international distributors, primarily selling over 30 lightweight and ergonomic wheelchair models to Japan and China, further solidifying its leadership position in the rehabilitation medical equipment market.
See More
